Lv1
48 积分 2024-10-05 加入
[Guideline of pelvic inflammatory disease (2019 revised edition)]
11个月前
已完结
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
1年前
已完结
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
1年前
已完结
Lung Cancer 2020
1年前
已完结
The ErbB/HER family of protein-tyrosine kinases and cancer
1年前
已完结
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
1年前
已完结
Mutation of the c-Cbl TKB Domain Binding Site on the Met Receptor Tyrosine Kinase Converts It into a Transforming Protein
1年前
已完结
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
1年前
已完结
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG
1年前
已关闭
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
1年前
已完结
皖公网安备34019202002308
